Market Overview - The chemical products sector experienced a decline of 0.55% on January 14, with Chenghe Technology leading the losses [1] - The Shanghai Composite Index closed at 4126.09, down 0.31%, while the Shenzhen Component Index rose to 14248.6, up 0.56% [1] Top Gainers in Chemical Sector - Qicai Chemical (300758) saw a significant increase of 20.01%, closing at 16.85 with a trading volume of 524,100 shares and a turnover of 832 million [1] - Changhua Chemical (301518) rose by 12.77%, closing at 44.60 with a trading volume of 124,200 shares and a turnover of 519 million [1] - Demei Chemical (002054) increased by 9.99%, closing at 8.81 with a trading volume of 420,300 shares and a turnover of 360 million [1] Top Losers in Chemical Sector - Chenghe Technology (688625) declined by 5.79%, closing at 58.71 with a trading volume of 88,500 shares and a turnover of 525 million [2] - Duofuduo (002407) fell by 4.31%, closing at 31.55 with a trading volume of 1,265,100 shares and a turnover of 404.6 million [2] - Kaisa Bio (688065) decreased by 3.97%, closing at 59.77 with a trading volume of 158,000 shares and a turnover of 965 million [2] Capital Flow Analysis - The chemical products sector experienced a net outflow of 1.757 billion from institutional investors, while retail investors saw a net inflow of 1.333 billion [2] - The top stocks with significant net inflows from retail investors include Qicai Chemical (300758) with a net inflow of 256 million [3] - Demei Chemical (002054) also had a notable net inflow of 108 million from retail investors [3]

Core Viewpoint - Biomanufacturing is identified as a key future industry in China's 14th Five-Year Plan, expected to create a market worth trillions in the next decade, driven by advancements in technology and policy support [2][5]. Group 1: Industry Overview - The biomanufacturing industry in China is nearing a total scale of 1 trillion yuan, with fermentation capacity accounting for over 70% of the global total [2][4]. - Shenzhen has become a hub for biomanufacturing, with 40% of newly established companies in this sector located there in the past three years, showcasing a significant industry clustering effect [4]. - The industry is supported by a comprehensive system of policy, funding, and technological advancements as outlined in the 14th Five-Year Plan [5]. Group 2: Key Enterprises - The article identifies 100 core enterprises in biomanufacturing, spanning the entire industry chain from upstream technology development to downstream commercial applications [7]. - Notable companies include: - Huada Technology, a leader in gene sequencing technology [17]. - Kaisa Biotech, which has achieved over 80% market share in the global long-chain dicarboxylic acid market [21]. - WuXi Biologics, representing China's capabilities in the global biopharmaceutical industry [27]. Group 3: Upstream Innovations - The upstream sector focuses on providing essential tools and technologies for research and production, with a shift towards domestic innovation and smart integration [16]. - Key trends include the localization of critical tools and the rise of AI-driven platform companies that enhance research efficiency [16][17]. - Over 75% of the 20 identified upstream enterprises are private, indicating a vibrant innovation landscape [16]. Group 4: Midstream Developments - The midstream sector is characterized by a dual structure of "upgraders" and "disruptors," with companies like Meihua Biotech and Chuaning Biotech leading in traditional fermentation while others like Kaisa Biotech innovate with new bioproducts [20][21]. - This segment contains the highest number of enterprises, with 40 out of the 100 identified companies, emphasizing the importance of production capacity and cost control [20]. Group 5: Downstream Applications - The downstream sector serves as a critical market for biomanufacturing, focusing on medical, consumer, and agricultural applications [25]. - Companies like Muyuan Foods exemplify the cost-saving potential of biomanufacturing in agriculture, while WuXi Biologics and Kelaiying represent the pharmaceutical sector's output capabilities [26][27]. - Future trends indicate a broadening of applications into new areas such as biobased textiles and environmental remediation [27].

Market Overview - The chemical products sector experienced a decline of 0.29% on January 13, with Qiaoyuan Co. leading the drop [1] - The Shanghai Composite Index closed at 4138.76, down 0.64%, while the Shenzhen Component Index closed at 14169.4, down 1.37% [1] Top Performers - Huaheng Biological (688639) saw a significant increase of 13.79%, closing at 41.34 with a trading volume of 419,600 shares and a transaction value of 1.721 billion [1] - Chenghe Technology (688625) rose by 12.29%, closing at 62.32 with a trading volume of 109,000 shares and a transaction value of 672 million [1] - Kaisa Biological (688065) increased by 12.14%, closing at 62.24 with a trading volume of 177,800 shares [1] Underperformers - Qiaoyuan Co. (301286) fell by 8.67%, closing at 47.41 with a trading volume of 53,000 shares and a transaction value of 258 million [2] - Hangqing Co. (002430) decreased by 6.99%, closing at 32.06 with a trading volume of 311,600 shares [2] - Taihe Technology (300801) dropped by 6.72%, closing at 30.39 with a trading volume of 173,200 shares [2] Capital Flow - The chemical products sector saw a net outflow of 642 million from institutional investors and 357 million from retail investors, while retail investors had a net inflow of 999 million [2] - The capital flow data indicates a mixed sentiment among different investor types within the sector [2] Individual Stock Capital Flow - Duoliangduo (002407) had a net inflow of 224 million from institutional investors, while it experienced a net outflow of 1.09 billion from retail investors [3] - Wanhu Chemical (600309) saw a net inflow of 189 million from institutional investors, with a net outflow of 76.596 million from retail investors [3] - Yahua Group (002497) had a net inflow of 154 million from institutional investors, while retail investors experienced a net outflow of 17.488 million [3]

重要内容提示： 安徽华恒生物科技股份有限公司（以下简称"公司"）于近日收到公司副总经理刘忠诚先生提交的书面辞 职报告，刘忠诚先生因个人原因，申请辞去公司副总经理职务。辞职后，刘忠诚先生不再担任公司任何 职务。 证券代码：688639 证券简称：华恒生物 公告编号：2026-001 安徽华恒生物科技股份有限公司 关于公司高级管理人员离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、高级管理人员离任情况 2026年1月13日 截至本公告披露日，刘忠诚先生未直接持有公司股份，不存在应当履行而未履行的承诺事项，刘忠诚先 生将继续严格遵守《上海证券交易所科创板股票上市规则》等规定。 刘忠诚先生在担任公司副总经理期间，恪尽职守、勤勉努力，公司董事会对刘忠诚先生自任职以来对公 司做出的贡献致以诚挚的感谢！ 特此公告。 安徽华恒生物科技股份有限公司董事会 (一)提前离任的基本情况 ■ (二)离任对公司的影响 根据相关法律法规和《公司章程》的有关规定，刘忠诚先生的辞职报告自送达公司董事会之日起生效， 其辞职不会影响公司相关工作的正 ...

证券日报网讯 1月12日，华恒生物发布公告称，公司于近日收到公司副总经理刘忠诚先生提交的书面辞 职报告，刘忠诚先生因个人原因，申请辞去公司副总经理职务。辞职后，刘忠诚先生不再担任公司任何 职务。 （编辑 任世碧） ...

每经AI快讯，华恒生物1月12日晚间发布公告称，刘忠诚先生因个人原因，申请辞去公司副总经理职 务。辞职后，刘忠诚先生不再担任公司任何职务。 （记者 曾健辉） 每经头条（nbdtoutiao）——年产量是传统大田120倍以上，1个人管理1栋楼！实探中国"植物工厂"：水 稻生产期从120天减到60天，没有虫害不用打农药 ...

证券代码：688639 证券简称：华恒生物 公告编号：2026-001 安徽华恒生物科技股份有限公司 关于公司高级管理人员离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 安徽华恒生物科技股份有限公司（以下简称"公司"）于近日收到公司副总 经理刘忠诚先生提交的书面辞职报告，刘忠诚先生因个人原因，申请辞去公司副 总经理职务。辞职后，刘忠诚先生不再担任公司任何职务。 一、高级管理人员离任情况 (二) 离任对公司的影响 根据相关法律法规和《公司章程》的有关规定，刘忠诚先生的辞职报告自送 达公司董事会之日起生效，其辞职不会影响公司相关工作的正常开展。刘忠诚先 生已按照公司离职管理制度做好交接工作。 截至本公告披露日，刘忠诚先生未直接持有公司股份，不存在应当履行而未 履行的承诺事项，刘忠诚先生将继续严格遵守《上海证券交易所科创板股票上市 规则》等规定。 刘忠诚先生在担任公司副总经理期间，恪尽职守、勤勉努力，公司董事会对 刘忠诚先生自任职以来对公司做出的贡献致以诚挚的感谢！ (一) 提前离任的基本情况 姓名 离任 ...

华恒生物公告称，近日收到副总经理刘忠诚书面辞职报告，其因个人原因申请辞去该职务，于2026年1 月12日提前离任，原定任期至2028年11月11日。辞职后，刘忠诚将不再担任公司任何职务。其辞职报告 自送达董事会起生效，不会影响公司正常运营，且已做好交接工作。截至公告披露日，刘忠诚未直接持 股，无未履行的承诺事项。 ...

Investment Rating - The industry investment rating is "Recommended" (maintained) [1] Core Insights - The new materials sector is a crucial direction for the chemical industry, currently experiencing rapid growth in downstream demand. With policy support and technological breakthroughs, domestic new materials are expected to accelerate their long-term growth. The report emphasizes that "one generation of materials leads to one generation of industries," highlighting the foundational nature of the new materials industry as the material basis for other industries [5][15]. Summary by Relevant Sections 1. Electronic Information Sector - Focus on semiconductor materials, display materials, and 5G materials [6] - Recent developments include NVIDIA's announcement of its new AI supercomputing platform, Vera Rubin, which has entered full production. The platform features six independent chips, with the Rubin GPU achieving a peak computing power of 50 Petaflops and a training performance 3.5 times that of its predecessor [7][37]. 2. Aerospace Sector - Focus on PI films, precision ceramics, and carbon fiber [8] - The successful acquisition of a production license for the AS700 manned airship marks a significant milestone for China's aerospace industry, indicating a shift towards standardized and commercialized production [9][10]. 3. New Energy Sector - Focus on photovoltaics, lithium-ion batteries, proton exchange membranes, and hydrogen storage materials [10] - A notable development is the introduction of the world's first all-solid-state battery by a Finnish startup, set to enter OEM mass production [11]. 4. Biotechnology Sector - Focus on synthetic biology and scientific services [12] - Beijing's economic development zone has announced measures to support the innovation and development of the synthetic biology manufacturing industry, aiming to establish a globally influential industry cluster by 2028 [13]. 5. Energy Conservation and Environmental Protection Sector - Focus on adsorbent resins, membrane materials, and biodegradable plastics [14] - The Guangxi government has issued a plan for green mine construction, aiming for over 90% of large and medium-sized mines to meet green standards by the end of 2028 [15]. 6. Industry Rating and Investment Strategy - The new materials sector is expected to benefit from the catalytic effects of downstream application sectors, gradually entering a prosperous cycle, thus maintaining a "Recommended" rating for the new materials industry [15].

兴业证券股份有限公司 关于安徽华恒生物科技股份有限公司 2025 年度现场检查报告 兴业证券股份有限公司（以下简称"兴业证券"或"保荐机构"）作为安徽华恒 生物科技股份有限公司（以下简称"华恒生物"或"公司"）向特定对象发行 A 股股 票的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司募集资金监 管规则》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运作》等相关规定，于 2025 年 12 月 23 日至 25 日对公司进行了现场检查。现将本次现场检查情况报告如下： 一、本次现场检查的基本情况 保荐机构于 2025 年 12 月 23 日至 25 日对华恒生物进行了现场检查。参加人 员为饶毅杰、郭飞腾、区绮琳。 在现场检查过程中，保荐机构结合华恒生物的实际情况，查阅、收集了华恒 生物自 2025 年 1 月 1 日至现场检查日的有关文件、资料，与公司管理人员进行 了访谈，实施了包括审核、查证、询问等必要程序，检查了公司治理和内部控制、 信息披露、公司的独立性以及与控股股东及其他关联方资金往来、募集资金使用、 关联交易、对外担保、重大对外投资以及经营 ...